Welcome to: Rimonabant Information Source (rimonabant purchase)

buy Rimonabant and lose weight
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 

Effective weight loss with Rimonabant

Rimonabant acomplia is a revolutionary new drug developed by the French company Sanofi. During the test period Acomplia is promising for the treatment of obesity and risk of additional authority. Drug is already approved in some European countries - Ireland, Sweden, Norway, Germany and UK Trade name Acomplia. In the United States, Acomplia is awaiting approval from the FDA office / probably in April 2007 /. Note for the U.S. to be rimonabant Zimulti. Rimonabant works by blocking the CB1 receptor, one of the two receptors found in a newly described physiological system called the endocannabino? System (EC System). Human trials began in 2002 and has shown a significant reduction of abdominal obesity, an independent marker for heart disease.

Rimonabant Pricelist

Please wait while we load the price list
Rimonabant is a useful weight loss aid. It helps control glucose and fat metabolism in the body and thereby brings about weight loss. Read on to know more about this weight loss pill. Approval of Rimonabant One of the effective weight loss drugs is Rimonabant. It is popular by the brand name Acomplia in European countries. Rimonabant works directly in the brain receptors and produce feelings of fullness. It is a powerful appetite suppressant drug. Rimonabant for weight loss treatment People in European countries including the UK take Rimonabant for attaining weight loss. Rimonabant diet pills have been approved by the European Union for use in European countries. In the UK, it is available only on private prescription.

NEW ORLEANS -- Evidence is mounting that rimonabant, shown effective for weight loss and smoking cessation, independently improves patients' cardiovascular risk profiles, F. Xavier Pi-Sunyer, M. D.reported at the annual scientific sessions of the American Heart Association. In the wake of the highly favorable results that the Rimonabant in Obesity--North America (RIO-NA) trial presented, the company plans to file for marketing approval for the investigational drug in the second quarter of 2005, a Sanofi-Synthelabo spokesman told this newspaper. Related Results Lancet, BMJ studies sound concern over anti-obesity drug rimonabantRimonabant improves cardiovascular risk profileRimonabant improves cardiovascular risk profileNew drug application for rimonabant pulledRimonabant enhanced weight loss success, improved lipids A total of 3,040 obese patients participated in RIO-NA, a 2-year randomized double-blind trial conducted at 72 U.